Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma – A phase II trial of the childhood liver tumour strategy group (SIOPEL)-Reference-Cited by-同舟云学术

Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma – A phase II trial of the childhood liver tumour strategy group (SIOPEL)

Published:2012-12 Issue:18 Volume:48 Page:3456-3464
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Zsíros József,Brugières Laurence,Brock Penelope,Roebuck Derek,Maibach Rudolf,Child Margaret,Morland Bruce,Casanova Michela,Pariente Daniele,Paris Claudia,Camargo Beatriz de,Ronghe Milind,Zimmermann Arthur,Plaschkes Jack,Czauderna Piotr,Perilongo Giorgio

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach – results of the first prospective study of the International Society of Pediatric Oncology;Pritchard;J Clin Oncol,2000

2. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94;Fuchs;Cancer,2002

3. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study;Katzenstein;J Clin Oncol,2002

4. High dose chemotherapy does not improve the overall survival of children with hepatoblastoma;Haberle;Pediatr Blood Cancer,2008

5. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma;Perilongo;N Engl J Med,2009

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver transplantation for pediatric liver malignancies;Liver Transplantation;2024-08-23

2. Successful Treatment of Refractory or Relapsed Hepatoblastoma With Autologous Hematopoietic Stem Cell Transplantation in Children;Journal of Pediatric Hematology/Oncology;2024-05-31

3. A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma;Journal of Hepatology;2024-04

4. The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution;eClinicalMedicine;2024-03

5. Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival;European Journal of Cancer;2024-03